Quick Read – ABBV trades at a PEG of 0.43 with a beta of just 0.28, while Skyrizi and Rinvoq combined for $6.6 billion in Q1 revenue. – ABBV’s 164% five-year gain dwarfs Pfizer’s negative 23% return, while Merck still faces a 2028 Keytruda patent cliff ABBV already navigated. -…
bVie raised its quarterly dividend 5.5% to $1.73 and lifted full-year EPS guidance, signaling strong income coverage heading into the July 31 report. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today
AbbVie (NYSE:ABBV) enters its July 31 Q2 earnings report with a 2.62% dividend yield, raised earnings guidance, and two blockbuster drugs growing above 20%. Skyrizi and Rinvoq have already replaced Humira as the company’s growth engines, strengthening AbbVie’s case as a combination of income, growth, and relatively low volatility. AbbVie Offers Growth at Just 18x Forward Earnings ABBV changes hands at $265.52 with a forward P/E of 18x and a PEG of 0.43, with a beta of 0.28.
Wall Street’s consensus target sits at $267.79 across 16 Buy and 8 Strong Buy ratings. AbbVie trades at a multiple below the S&P 500 average paired with growth prospects and roughly a quarter of the market’s volatility. A 5.5% Dividend Increase Strengthens the Income Case AbbVie’s annualized dividend of $6.74 per share means the stock offers a 2.62% yield.